- Report
- July 2023
- 238 Pages
China
From €3814EUR$4,000USD£3,269GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$3,932USD£3,105GBP
- Report
- February 2022
- 80 Pages
Africa
From €3619EUR$3,795USD£3,101GBP
- Report
- February 2022
- 40 Pages
Brazil
From €2474EUR$2,595USD£2,121GBP
- Report
- February 2022
- 40 Pages
China
From €2474EUR$2,595USD£2,121GBP
- Report
- February 2022
- 40 Pages
France
From €2474EUR$2,595USD£2,121GBP
- Report
- February 2022
- 40 Pages
Germany
From €2474EUR$2,595USD£2,121GBP
- Report
- February 2022
- 40 Pages
Ireland
From €2474EUR$2,595USD£2,121GBP
- Report
- February 2022
- 40 Pages
Japan
From €2474EUR$2,595USD£2,121GBP
- Report
- February 2022
- 40 Pages
Russia
From €2474EUR$2,595USD£2,121GBP
- Report
- February 2022
- 40 Pages
South Korea
From €2474EUR$2,595USD£2,121GBP
- Report
- February 2022
- 40 Pages
United States
From €2474EUR$2,595USD£2,121GBP
- Report
- February 2022
- 40 Pages
Vietnam
From €2474EUR$2,595USD£2,121GBP
- Report
- July 2023
- 104 Pages
China
From €1716EUR$1,800USD£1,471GBP
- Report
- November 2021
- 220 Pages
Global
From €2288EUR$2,400USD£1,961GBP
- Report
- April 2023
- 263 Pages
Global
From €3404EUR$3,570USD£2,918GBP
- Report
- April 2023
- 160 Pages
Global
From €5720EUR$5,999USD£4,903GBP
- Report
- April 2023
- 147 Pages
Global
From €5720EUR$5,999USD£4,903GBP
- Report
- March 2023
- 162 Pages
Global
From €2669EUR$2,799USD£2,287GBP
The Anti Rheumatic market is a subset of the Immune Disorders Drugs market, which focuses on the treatment of rheumatic diseases. These diseases are caused by an abnormal immune response, which can lead to inflammation and joint pain. Anti Rheumatic drugs are used to reduce inflammation and pain, as well as to prevent further damage to the joints. These drugs can be administered orally, intravenously, or topically. Commonly used Anti Rheumatic drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic response modifiers.
Some companies in the Anti Rheumatic market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more